Propanc Biopharma, Inc. (PPCB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.53 Million USD | 13.54% |
| 2023 | -1.77 Million USD | 11.41% |
| 2022 | -1.99 Million USD | -9.36% |
| 2021 | -1.81 Million USD | 47.28% |
| 2020 | -3.49 Million USD | -31.42% |
| 2019 | -2.61 Million USD | 33.99% |
| 2018 | -3.95 Million USD | 31.02% |
| 2017 | -5.73 Million USD | 16.79% |
| 2016 | -6.89 Million USD | -304.27% |
| 2015 | -1.7 Million USD | -124.21% |
| 2014 | -760.68 Thousand USD | 43.98% |
| 2013 | -1.35 Million USD | 88.28% |
| 2012 | -11.6 Million USD | -418.92% |
| 2011 | -2.23 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -432.19 Thousand USD | -164.49% |
| 2024 Q3 | -416.1 Thousand USD | 12.11% |
| 2024 Q4 | -254.13 Thousand USD | 32.39% |
| 2024 Q1 | -417.21 Thousand USD | 73.31% |
| 2023 FY | - USD | 11.41% |
| 2023 Q1 | -549.72 Thousand USD | 6.73% |
| 2023 Q4 | -204.03 Thousand USD | 46.39% |
| 2023 Q3 | -380.58 Thousand USD | 36.76% |
| 2023 Q2 | -601.83 Thousand USD | -9.48% |
| 2022 Q3 | -501.69 Thousand USD | -24.5% |
| 2022 FY | - USD | -9.36% |
| 2022 Q4 | -589.41 Thousand USD | -17.48% |
| 2022 Q2 | -402.96 Thousand USD | 17.0% |
| 2022 Q1 | -485.52 Thousand USD | 33.16% |
| 2021 FY | - USD | 47.28% |
| 2021 Q1 | -382.72 Thousand USD | 28.47% |
| 2021 Q3 | -427.42 Thousand USD | -56.23% |
| 2021 Q4 | -726.41 Thousand USD | -69.95% |
| 2021 Q2 | -273.58 Thousand USD | 28.52% |
| 2020 Q3 | -606.44 Thousand USD | 56.15% |
| 2020 Q4 | -535.02 Thousand USD | 11.78% |
| 2020 FY | - USD | -31.42% |
| 2020 Q1 | -908.77 Thousand USD | -8.75% |
| 2020 Q2 | -1.38 Million USD | -52.18% |
| 2019 Q2 | -757.25 Thousand USD | -68.9% |
| 2019 Q3 | -571.13 Thousand USD | 24.58% |
| 2019 Q4 | -835.68 Thousand USD | -46.32% |
| 2019 FY | - USD | 33.99% |
| 2019 Q1 | -448.33 Thousand USD | 12.3% |
| 2018 Q3 | -806.56 Thousand USD | 43.85% |
| 2018 Q2 | -1.43 Million USD | -19.37% |
| 2018 Q1 | -1.2 Million USD | -8.51% |
| 2018 Q4 | -511.2 Thousand USD | 36.62% |
| 2018 FY | - USD | 31.02% |
| 2017 FY | - USD | 16.79% |
| 2017 Q4 | -1.1 Million USD | 28.27% |
| 2017 Q3 | -1.54 Million USD | 18.99% |
| 2017 Q2 | -1.9 Million USD | -62.6% |
| 2017 Q1 | -1.17 Million USD | 66.03% |
| 2016 FY | - USD | -304.27% |
| 2016 Q1 | -1 Million USD | -43.32% |
| 2016 Q2 | -1.14 Million USD | -13.77% |
| 2016 Q3 | -1.29 Million USD | -12.85% |
| 2016 Q4 | -3.45 Million USD | -167.73% |
| 2015 Q1 | -238.13 Thousand USD | -93.82% |
| 2015 Q4 | -701.36 Thousand USD | -35.78% |
| 2015 Q3 | -516.55 Thousand USD | -107.08% |
| 2015 Q2 | -249.44 Thousand USD | -4.75% |
| 2015 FY | - USD | -124.21% |
| 2014 Q3 | -104.3 Thousand USD | 53.68% |
| 2014 FY | - USD | 43.98% |
| 2014 Q1 | -308.31 Thousand USD | -65.15% |
| 2014 Q2 | -225.18 Thousand USD | 26.96% |
| 2014 Q4 | -122.86 Thousand USD | -17.8% |
| 2013 Q3 | -229.36 Thousand USD | 46.7% |
| 2013 Q4 | -186.68 Thousand USD | 18.61% |
| 2013 FY | - USD | 88.28% |
| 2013 Q1 | -479.36 Thousand USD | 81.16% |
| 2013 Q2 | -430.3 Thousand USD | 10.23% |
| 2012 Q2 | -2.87 Million USD | -1317.34% |
| 2012 Q3 | -3.09 Million USD | -7.47% |
| 2012 Q1 | -203.13 Thousand USD | 68.99% |
| 2012 FY | - USD | -418.92% |
| 2012 Q4 | -2.54 Million USD | 17.78% |
| 2011 Q3 | -507.87 Thousand USD | -3.21% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | -655.06 Thousand USD | -28.98% |
| 2011 Q2 | -492.08 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 97.838% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 74.092% |
| SQZ Biotechnologies Company | -64.14 Million USD | 97.605% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 91.157% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.633% |
| Mesoblast Limited | -62.38 Million USD | 97.538% |
| Genus plc | 73.7 Million USD | 102.084% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 76.767% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 56.694% |
| Marizyme, Inc. | -34.28 Million USD | 95.519% |
| ContraFect Corporation | -64.99 Million USD | 97.637% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 82.489% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 66.063% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -9.576% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 41.914% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 33.9% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -196.508% |
| Accustem Sciences Inc. | -3.74 Million USD | 59.0% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 96.815% |
| EV Biologics, Inc. | -1.26 Million USD | -21.222% |
| Q BioMed Inc. | -617.62 Thousand USD | -148.701% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 143.002% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -142.89% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 32.762% |
| Biomind Labs Inc. | -1.03 Million USD | -48.475% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 115.552% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 78.551% |
| Skye Bioscience, Inc. | -13.54 Million USD | 88.662% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -3.27% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -6044.196% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 60.455% |
| IMV Inc. | -35.52 Million USD | 95.676% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 90.321% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 38.606% |
| GB Sciences, Inc. | -1.41 Million USD | -8.181% |
| Alpha Cognition Inc. | -9.7 Million USD | 84.174% |
| HST Global, Inc. | -5303.00 USD | -28865.661% |
| CSL Limited | 4.78 Billion USD | 100.032% |
| Halberd Corporation | -74.27 Thousand USD | -1967.945% |
| Enzolytics Inc. | -2.12 Million USD | 27.614% |
| Resverlogix Corp. | -11.74 Million USD | 86.918% |
| Affymax, Inc. | -14.29 Million USD | 89.255% |
| SYBLEU INC | -141.57 Thousand USD | -985.003% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 49.852% |
| argenx SE | -216.02 Million USD | 99.289% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.224% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 226.216% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -2.478% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 505.457% |
| AVAX Technologies, Inc. | -6.11 Million USD | 74.871% |
| Zenith Capital Corp. | -8.6 Million USD | 82.151% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.382% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8717.226% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 37.213% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -772.634% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 96.125% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 46.892% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -46.806% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 22944.274% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 12.226% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 20.035% |
| BioStem Technologies, Inc. | -7.55 Million USD | 79.665% |
| ONE Bio Corp. | 13.61 Million USD | 111.284% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -748.233% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 25.326% |
| Agentix Corp. | -1.37 Million USD | -11.977% |
| LadRx Corporation | 412.28 Thousand USD | 472.572% |
| Cell Source, Inc. | -4.27 Million USD | 64.048% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -318.29% |
| Regen BioPharma, Inc. | 1.46 Million USD | 204.781% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -63.942% |
| NovAccess Global Inc. | -1.03 Million USD | -48.44% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 117.349% |
| Itoco Inc. | -1.86 Million USD | 17.814% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -304.628% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -37.639% |
| Kadimastem Ltd | -2.62 Million USD | 41.47% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -542.295% |
| CytoDyn Inc. | -18.02 Million USD | 91.48% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1843.652% |
| Mobile Lads Corp. | -2.24 Million USD | 31.462% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -12460.708% |
| Qrons Inc. | -40.08 Thousand USD | -3732.362% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -216.269% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 391.231% |
| Rebus Holdings, Inc. | -951 Thousand USD | -61.519% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -44.636% |
| International Stem Cell Corporation | 202 Thousand USD | 860.42% |
| Bioxytran, Inc. | -3.82 Million USD | 59.791% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2818.026% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 37.608% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 95.718% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -3313.442% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 43.899% |
| Neutra Corp. | -181.24 Thousand USD | -747.489% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 92.38% |
| PureTech Health plc | -11.62 Million USD | 86.789% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 92.38% |
| IXICO plc | -707 Thousand USD | -117.263% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 80.012% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 96.823% |
| CSL Limited | 4.73 Billion USD | 100.032% |
| Cellectis S.A. | -92.63 Million USD | 98.342% |